Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viet Nam Pharmaceutical - JSCHSTC:DVN -1.73%82 3-Year EBITDA Growth Rate is 59.80% as of Jun. 2026, which is 221% above its 10-year median of 18.65. GuruFocus rates HSTC:DVN with a GF Score™ of 82/100 and a GF Value™ of ₫21,871.73 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 808 Drug Manufacturers companies, Viet Nam Pharmaceutical - JSC ranks better than 90.84% on this metric.
During the past 12 months, Viet Nam Pharmaceutical - JSC's average EBITDA Per Share Growth Rate was 71.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 59.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 24.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Viet Nam Pharmaceutical - JSC was 59.80% per year. The lowest was -13.90% per year. And the median was 18.65% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Viet Nam Pharmaceutical - JSC 3-Year EBITDA Growth Rate Related Terms
HSTC:DVN vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viet Nam Pharmaceutical - JSC's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viet Nam Pharmaceutical - JSC 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viet Nam Pharmaceutical - JSC's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Viet Nam Pharmaceutical - JSC's 3-Year EBITDA Growth Rate falls into.
Viet Nam Pharmaceutical - JSC 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 59.80% mean?
Viet Nam Pharmaceutical - JSC (HSTC:DVN) has a 3-Year EBITDA Growth Rate of 59.80% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Viet Nam Pharmaceutical - JSC and its competitors. This is 221% above median its historical median of 18.65. According to the industry distribution chart, Viet Nam Pharmaceutical - JSC ranks #74 out of 808 companies in the Drug Manufacturers industry, placing it in the top 9.2%.
Is Viet Nam Pharmaceutical - JSC's 3-Year EBITDA Growth Rate too high?
Viet Nam Pharmaceutical - JSC's current 3-Year EBITDA Growth Rate of 59.80% is 221% above median its 10-year median of 18.65. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Viet Nam Pharmaceutical - JSC's value of 59.80% is 571.9% above this industry median. Based on the distribution chart, Viet Nam Pharmaceutical - JSC ranks #74 out of 808 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Viet Nam Pharmaceutical - JSC has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Viet Nam Pharmaceutical - JSC's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Viet Nam Pharmaceutical - JSC ranks #74 out of 808 companies for 3-Year EBITDA Growth Rate. This places Viet Nam Pharmaceutical - JSC in the top 9% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Viet Nam Pharmaceutical - JSC's value of 59.80% is 571.9% above this benchmark. While the company's 10-year median is 18.65 vs. the industry median of 8.90, Viet Nam Pharmaceutical - JSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viet Nam Pharmaceutical - JSC's current 3-Year EBITDA Growth Rate of 59.80% is 571.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Viet Nam Pharmaceutical - JSC and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viet Nam Pharmaceutical - JSC's current 3-Year EBITDA Growth Rate is 59.80%, which is 221% above median its own 10-year median of 18.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viet Nam Pharmaceutical - JSC stock overvalued right now?
Based on GuruFocus' analysis, Viet Nam Pharmaceutical - JSC (HSTC:DVN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫21,871.73, compared to a current price of ₫17,300.00 — trading 20.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 59.80%, which is 221% above median its 10-year median of 18.65 and 571.9% above the Drug Manufacturers industry median of 8.90. Viet Nam Pharmaceutical - JSC's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Viet Nam Pharmaceutical - JSC (HSTC:DVN), the current 3-Year EBITDA Growth Rate is 59.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viet Nam Pharmaceutical - JSC (HSTC:DVN) Overvalued in 2026?
Based on GuruFocus' analysis, Viet Nam Pharmaceutical - JSC stock appears to be undervalued.
The current stock price of ₫17,300.00 is trading 20.9% below its estimated GF Value™ of ₫21,871.73.
GuruFocus considers Viet Nam Pharmaceutical - JSC to be Modestly Undervalued.
Key valuation signals for HSTC:DVN:
3-Year EBITDA Growth Rate: 59.80% (221% above median its 10-year median of 18.65)
GF Value™: ₫21,871.73 vs. price of ₫17,300.00 (20.9% below fair value)
Industry Position: 571.9% above the Drug Manufacturers median (#74 of 808)
No single metric tells the full story. See the HSTC:DVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viet Nam Pharmaceutical Corp - JSC is engaged in the manufacturing of drugs. The company provides testing services for drugs and medicinal ingredients.
82GF Score
Get the complete analysis for HSTC:DVN
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSTC:DVN has been successfully added to your 
